Palisade Bio Initiates Phase 1 Clinical Trial for PALI-2108
Palisade Bio, Inc. (NASDAQ: PALI), a pioneering biopharmaceutical company, proudly announces a significant advancement in its clinical development journey. The company has successfully dosed its first subject in a Phase 1 clinical study for PALI-2108, an innovative orally administered PDE4 inhibitor prodrug aimed at treating moderate-to-severe ulcerative colitis (UC).
Understanding the Phase 1 Clinical Study
The Phase 1 study is designed as a single-center, double-blind, placebo-controlled trial. It aims to comprehensively assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of PALI-2108 in both healthy volunteers and patients afflicted with UC. Currently, patient screening is actively taking place to recruit eligible participants for this groundbreaking research.
Importance of Safety and Tolerability Assessments
CEO JD Finley expressed enthusiasm about this milestone, emphasizing that dosing the first subject is a pivotal step for Palisade Bio as it transitions into a clinical-stage entity. The company eagerly anticipates the topline data release, expected in the first half of the upcoming year.
Objectives and Methodology of the Study
The single-center Phase 1 study's primary objective is to evaluate the safety and pharmacokinetics of PALI-2108 in healthy subjects, as well as the effects of the drug in UC patients. The study includes a variety of tests, intending to determine how the body processes this new compound. Notably, PALI-2108 is a new chemical entity and represents an exciting potential advancement in treating these challenging conditions.
Study Design Details
This comprehensive study features several components. It begins with single ascending dose (SAD) cohorts, followed by crossover evaluations to understand the influence of food on pharmacokinetics. Additional multiple ascending dose (MAD) cohorts will follow suit, concluding with a cohort of multiple doses administered to UC patients. By utilizing biomarker analysis, including serum high sensitivity C-reactive protein (hsCRP) and fecal calprotectin, the study aims to gather insights that pinpoint the therapy’s efficacy and overall impact on patients' health.
The Role of Biomarkers in Evaluation
Biomarkers are vital in understanding PALI-2108's effects. By assessing levels of metabolites, PDE4 expression, and cyclic adenosine monophosphate (cAMP) concentrations, along with Absolute Lymphocyte Count (ALC) and other pharmacodynamic indicators, researchers aim to gain crucial insights into the drug's mechanisms and its potential benefits for patients suffering from UC.
Palisade Bio’s Vision and Commitment
Palisade Bio is dedicated to transforming the landscape for patients dealing with autoimmune, inflammatory, and fibrotic diseases. By employing cutting-edge therapeutics, the company believes it can significantly enhance treatment outcomes for these conditions. A focused and targeted approach underlies their research, setting a bright future for innovations stemming from their discoveries.
Frequently Asked Questions
What is PALI-2108?
PALI-2108 is an orally administered PDE4 inhibitor prodrug being developed by Palisade Bio for the treatment of ulcerative colitis.
What are the primary goals of the Phase 1 study?
The Phase 1 study primarily focuses on evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of PALI-2108 in healthy volunteers and patients with ulcerative colitis.
When can we expect data from the clinical study?
The topline data from the clinical study is anticipated to be released in the first half of the upcoming year.
What role do biomarkers play in this clinical research?
Biomarkers help in assessing the drug's effects and understanding its mechanism of action, crucial for determining the efficacy of PALI-2108.
Who is heading the research for Palisade Bio?
The research efforts for Palisade Bio are led by a dedicated team, including CEO JD Finley, who emphasizes the company's commitment to advancing innovative treatments.
